Background: Pulmonary hypertension (PH) is a disease that affects the adult or infant population. Dehydroepiandrosterone (DHEA), a steroid hormone, has been previously shown to prevent and to reverse PH in an adult rat model. We thus investigated its effect in a rat-pup model of chronic hypoxic PH. Methods: Animals were maintained for 3 wk in a hypobaric chamber to induce PH, with or without concomitant treatment with DHEA (30 mg/kg every alternate day). results: DHEA significantly reduced mean pulmonary artery pressure (measured by right cardiac catheterization), pulmonary artery remodeling (evaluated by histology), and rightventricular hypertrophy (measured by echography and by the Fulton index). At the level of the pulmonary artery smooth muscle cell (PASMC), DHEA increased activity and expression of the large-conductance Ca2+-activated potassium channel (BK Ca ) (assessed by means of the patch clamp technique). DHEA also inhibited both serotonin-and KCl-induced contraction and smooth muscle cell proliferation. conclusion: Collectively, these results indicate that DHEA prevents PH in infant rats and may therefore be clinically relevant for the management of PH in human infants. P ulmonary hypertension (PH) is a disease that affects both adults and infants. PH is characterized by increased pulmonary vascular pressure and resistance, which can lead, in rare cases in infants, to right-ventricular failure and ultimately to death (1). Increased reactivity to agonists and remodeling of small pulmonary arteries (PAs) are landmarks of PH (2,3). In infants, there are a variety of PH phenotypes, some of which are specific to this age group: (i) PH secondary to congenital heart disease with a left-right shunt, (ii) persistent PH of the newborn due to the absence of a drop in neonatal pulmonary resistance, (iii) acute or chronic pulmonary disease induced by hypoxemia, and (iv) idiopathic forms (4,5). Pharmacological treatments that mainly aim at vasodilating PAs, e.g., prostanoid analog, endothelin receptor antagonists, or phosphodiesterase inhibitors (2,6), still need to be comprehensively evaluated in pediatric patients. It is thus essential to develop new treatments to prevent and/or reverse PH in this population.Dehydroepiandrosterone (DHEA) is the most abundant adrenal steroid, and serum concentration of its sulfate ester is approximately 20-fold higher than that of any other circulating steroid hormone (7,8). In different models of adult rats with PH, we (9) and others (10,11) have shown that DHEA prevents and reverses PH and the resulting right-ventricular (RV) hypertrophy as well as small PA remodeling. However, similar studies have not been performed in newborn or infant animals. We have thus investigated the effect of DHEA in a model of infant rats in which PH was induced. We have observed that chronic treatment with DHEA (30 mg/kg every alternate day) is able to prevent PH and its associated cardiovascular alterations such as RV hypertrophy, pulmonary vascular hyperreactivity, and smooth muscle cell proliferat...